Allurion Technologies, Inc 8-K, filed Jun 26, 2024
Allurion Technologies, Inc. (ALUR)
About this 8-K
Allurion Technologies, Inc filed this 8-K on June 26, 2024, reporting on events of June 25, 2024.
Items reported
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Its Charter)
| (State of Incorporation or Organization) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
(Address of Principal Executive Offices, including Zip Code)
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading |
Name of each exchange | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 7.01 | Regulation FD Disclosure. |
On June 25, 2024, Allurion Technologies, Inc. (the “Company”) made available an investor presentation on the Company’s website.
A copy of the investor presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The exhibit furnished under Item 7.01 of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
EXHIBIT INDEX
| Exhibit No. |
Description | |
| 99.1 | Investor Presentation, dated June 25, 2024 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Allurion Technologies, Inc. | ||||||
| Date: June 25, 2024 | By: | /s/ Brendan Gibbons | ||||
| Brendan Gibbons | ||||||
| Chief Legal Officer | ||||||
Exhibit 99.1 Investor Presentation
1 Disclaimer This presentation, the information contained herein and the materials accompanying it (together, this “presentation”) contains confidential, material and non-public information regarding Allurion Technologies, Inc. (the “Company” or “us”) and is provided to the recipients (“you”) of this presentation on the condition that you agree to hold it in strict confidence and not reproduce, disclose, forward or distribute it in whole or in part to others at any time without the prior written consent of the Company. By accepting this presentation, you expressly agree to maintain the confidentiality of the material and information contained or accompanying it and to use this presentation in accordance with your contractual obligations to the Company and applicable law, including federal and state securities laws. This presentation contains forward-looking statements within the meaning of the federal securities laws, which are statements that involve substantial risks and uncertainties. Forward-looking statements generally relate to future events or the Company’s future financial or operating performance. All statements other than statements of historical fact included in this presentation, including statements regarding the Company’s strategy, future operations, financial position, estimated revenue and losses, projected costs, volume of procedures, prospects, plans, and objectives of management are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “shall,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue” or the negative of these words or other similar terms or expressions that concern the Company’s expectations, strategy, plans or intentions. The Company has based the forward-looking statements contained in this presentation primarily on management’s current beliefs and the Company’s current expectations and projections about future events and trends that it believes may affect its business, results of operations, financial condition, and prospects. Moreover, the Company operates in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for the Company to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this presentation. The results, events, and circumstances reflected in the forward-looking statements may not be achieved or occur, and actual results, events, or circumstances could differ materially from those described in the forward-looking statements. There are a number of factors, many of which are beyond the Company’s control, that could cause actual results to differ materially from the results anticipated by these forward-looking statements, including, among others: the Company’s expectations regarding its revenue, expenses, and other operating results; the Company’s ability to acquire new customers or distributors and grow its customer base; the Company’s ability to successfully retain existing customers and distributors and expand sales within its existing customer base; the Company’s ability to launch its existing products in new markets or launch new product developments and offerings, including the Company’s digital health platform and artificial intelligence tools; regulatory approvals for the Company’s products, including approval of the Company’s gastric balloon in the U.S. and any expanded label uses; future investments in developing and enhancing the Company’s business; the Company’s expectations regarding its ability to expand; the Company’s anticipated capital expenditures and its estimates regarding the Company’s capital requirements; investments in the Company’s selling and marketing efforts; the Company’s ability to compete effectively with existing competitors and new market entrants; the total addressable markets for the Company’s products; the Company’s reliance on its senior management team and its ability to identify, recruit, and retain skilled personnel; the Company’s ability to effectively manage its growth; economic and industry trends and other macroeconomic factors, such as fluctuating interest rates, rising inflation and consumer sentiment; and the impact of global pandemics, health crises, political conflicts and other global financial, economic, and political events on the Company’s industry, business, and results of operations. Should one or more of these risks or uncertainties materialize, or should any of the Company’s assumptions prove incorrect, the Company’s actual results may vary in material respects from those projected in these forward-looking statements. Factors or events that could cause the Company’s actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The forward-looking statements made in this presentation relate only to events as of the date on which the statements are made. The Company undertakes no obligation to update any forward-looking statements made in this presentation to reflect events or circumstances after the date of this presentation or to reflect new information or the occurrence of unanticipated events, except as required by applicable law. The Company may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on the Company’s forward- looking statements. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our most annual report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”), as well as discussions of potential risks, uncertainties and other important factors in our other subsequent filings with the SEC. This presentation contains financial forecasts with respect to the Company’s projected financial results for the Company for the periods indicated. These projections should not be relied upon as being necessarily indicative of future results. The assumptions and estimates underlying the prospective financial information are inherently uncertain and are subject to a wide variety of significant business, economic and competitive risks and uncertainties that could cause actual results to differ materially from those contained in the prospective financial information. Actual results may differ materially from the results contemplated by the projected financial information contained in Confidential Information this presentation and the inclusion of such information should not be regarded as a representation by any person that the results reflected in such information will be achieved. There can be no assurance that the prospective results are indicative of the future performance of the Company or that actual results will not differ materially from those presented in the prospective financial information. © 2024 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION
2 Disclaimer (Continued) This presentation is made pursuant to Section 5(d) and/or Rule 163B of the Securities Act of 1933, as amended (the “Securities Act”), and is intended solely for investors that are “qualified institutional buyers” as defined in Rule 144A under the Securities Act, or institutions that are “accredited investors” as defined in Rule 501 of Regulation D under the Securities Act, solely for the purposes of familiarizing such investors with the Company and determining whether such investors might have an interest in a securities offering contemplated by the Company. Any such offering of securities will only be made by means of a registration statement (including a prospectus) filed with the U.S. Securities and Exchange Commission, after such registration statement becomes effective. No such registration statement has been publicly filed, or become effective, as of the date of this presentation. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This presentation does not purport to contain all of the information that may be required to evaluate any investment in the Company or any of its securities and should not be relied upon to form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. This presentation is intended to present background information on the Company, its business and the industry in which it operates and is not intended to provide complete disclosure upon which an investment decision could be made. The merit and suitability of an investment in the Company should be independently evaluated and any person considering such an investment in the Company is advised to obtain independent advice as to the legal, tax, accounting, financial and other related advice prior to making an investment. Any decision to purchase securities in any offering the Company may make in the future should be made solely on the basis of information contained in any prospectus that may be prepared by the Company in final form in relation to any such proposed offering and which would supersede this presentation and information contained herein in its entirety. None of the Company or any of its affiliates, directors, officers, employees, advisers, representatives or any other person makes any representation or warranty, expressed or implied, as to the accuracy or completeness of this presentation or any of the information contained herein, or any other written or oral communication transmitted or made available to you or your affiliates or representatives. Accordingly, none of the Company or any of its affiliates, directors, officers, employees, advisers, representatives or any other person shall be liable for any direct, indirect or consequential loss or damages suffered by any person based, in whole or in part, on the presentation or any information contained herein or any other written or oral communication transmitted or made available to you or your affiliates or representatives, including, without limitation, with respect to errors therein or omissions therefrom, and any such liability is expressly disclaimed to the fullest extent permitted by law. made available to Unless otherwise indicated, information contained in this presentation concerning the Company’s industry, competitive position and the markets in which it operates is based on information from independent industry and research organizations, other third-party sources, and management estimates. Management estimates are derived from publicly available information released by independent industry analysts and other third‐party sources, as well as data from the Company’s internal research, and are based on assumptions made by the Company upon reviewing such data, and the Company’s experience in, and knowledge of, such industry and markets, which the Company believes to be reasonable. While the Company believes that such third party information is reliable, the Company has not independently verified, and makes no representation as to the accuracy or completeness of, such third party information. All trademarks, service marks, and trade names appearing in this presentation are the property of their respective holders and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of the Company. © 2024 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION
3 Transaction Summary Issuer Allurion Technologies, Inc. Ticker (Listing) ALUR (NYSE) (1) Offering Amount $20.0 million (100% primary); includes common stock and warrants Warrants will be immediately exercisable at an exercise price equal to the offer price and will expire five years from the Warrants date of issuance; 100% warrant coverage To fund clinical trials, commercial sales, research and development, and for working capital and other general corporate Use of Proceeds purposes Lock-Up Period 90 days for Company, Directors & Officers Book-Runners Jefferies, TD Cowen Co-Manager Roth Capital Partners th Expected Pricing June 27 , 2024 (post-market close) 1) RTW Investments, LP (“RTW”), a significant stockholder, has indicated an interest in investing an aggregate of $3.0 million in this offering and in a concurrent private placement of a newly-created series of preferred stock, Series A convertible preferred stock (the “Series A preferred stock”) and accompanying private placement warrants. © 2024 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION
4 Investment Highlights Allurion is well-positioned for growth in 2024 and beyond 1 Large addressable market that is continuing to grow; $54B obesity treatment market expected by 2030 Innovative gastric balloon technology that drives durable total body weight loss (14% with one balloon and 23% with two 2 balloons), with excellent safety profile 3 Strong international business with $53M in revenue and 78% GM in 2023, with path to profitability 4 Robust procedure volume growth; targeting ~20% YoY growth in 2024 5 FDA AUDACITY trial data expected by year-end 2024 enabling entry into $18B U.S. opportunity, if approved by the FDA 6 Commercializing AI-powered digital platform globally, including in the U.S. market; leveraging tailwinds from GLP-1s © 2024 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION
5 Obesity Is A Significant Problem With Society-Wide Health And Economic Ramifications Massive market opportunity with $54B revenue opportunity by 2030 The Problem The Opportunity 60 50 40 30 20 10 0 2024 2025 2026 2027 2028 2029 2030 US revenues Ex-US revenues $54B obesity treatment market expected by 2030 Growth driven primarily by GLP-1 drug adoption and fueled 4 by growing interest in weight management solutions 1) World Obesity Federation, “Global Obesity Observatory”. 2) Telem, D., Greenstein A., Wolfe B. (2024), Outcomes of bariatric surgery, UpToDate. 3) Murtha et. al. Individual-level barriers to bariatric surgery from patient and provider perspectives: A qualitative study. doi: 10.1016/j.amjsurg.2021.12.022. 4) Morgan Stanley, “Unlocking the Obesity Challenge”. © 2024 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION $ Billion
6 Other Weight-Loss Therapies Bariatric surgical procedures and other existing balloons have notable shortcomings Flawed Poor High Poor Go-To-Market Experience Risks Economics Limited Channels Execution Lack of post- Invasive All-in costs for Existing approach Previous procedure patient procedures are cash-pay bariatric lacks scalable companies failed monitoring and inherently risky in surgery is infrastructure and to embrace behavior a high BMI ~$14,000 on training to deliver modern-day modification population, average and up to comprehensive digital advertising programs especially where ~$33,000, with weight loss and account patients undergo limited insurance programs training to 1 2 anesthesia coverage drive growth 1) ASA. 2) Doble et al. Obes Surg. 2017; 27(8): 2179-2192. © 2024 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION
We believe the Allurion balloon solves shortcomings of other treatments The world’s first and only Procedureless™ weight loss device A breakthrough in simplicity 1* Procedureless – swallowed in 15-minute office visit without surgery, endoscopy, or anesthesia Unintrusive – ~4 months after placement, a time-activated release valve constructed from a 1 proprietary polymer opens, allowing the balloon to pass naturally through the GI tract Innovative – Covered by over 50 patents and made from biocompatible polyurethane designed 1* to be gentle on the stomach lining Significantly improved patient experience 2- 8 Lower serious adverse event rate – 10x lower than other liquid-filled balloons Lower intolerance requiring balloon removal – ~1–3% intolerance rate vs. 14–17% for 12-month 9-10 endoscopic balloons Increasing global availability First Allurion Balloons available on NHS in UK – in discussions with healthcare trusts to roll out more broadly FDA AUDACITY trial readout expected by year end 2024 1) Taha et al. Obesity Surgery. 2020. 5) Moore et al., 2020. 9) Jamal MH et al. Obesity Surgery, 2021. 2) Ponce et al. Surg Obes Relat Dis. 2015. 6) Abu Dayyeah et al., 2021. 10) Abu Dayyeh BK et al. Lancet, 2021. 3) US FDA Post-Approval Studies Database Application #P140012. 7) Allurion Enlighten Trial. 4) Orbera Pivotal Trial NCT00730327. 8) Ienca et al. 2020. Note: *The Allurion Balloon is an investigational device in the United States and has not been cleared or approved by the U.S. Food and Drug Administration (FDA). In rare cases, endoscopic or surgical intervention © 2024 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION may be required for removal.
8 The Allurion Balloon Is Paired With The Virtual Care Suite Allurion Allurion Patient App Connected Scale 3 Tracks weight and Analyzes data, body composition, provides real-time empowering and insights, enables enabling patients to sharing with care reach their goals Allurion team, and syncs with the user’s own Insights smartwatch to track activity and sleep Coach Iris Patient and clinic-level data for improved patient care and clinic management AI-powered virtual weight loss coach that supports patients 24/7 © 2024 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION
9 Comprehensive Clinical Data Supports The Allurion Balloon’s Efficacy Profile Allurion Balloon Led to 96% of Weight Loss Sequential Allurion Treatment 1 2 3 15% Weight Loss in Just 4 Months Maintained After 1 Year Led to 23% Weight Loss After two sequential balloons, % TBWL ≥30% was Weight Loss achieved in 26% of patients (% TBWL) 15% Weight (kg) % TBWL 13% 23% 96% weight 22 maintenance 13.9% on average 13.4% 10% 15 14% 7% 6% 5% 5% 3% 0% 0% %TBWL Weight Loss (kg) Weight Loss % 1 Balloon 2 Balloons 4 Months 1 Year Allurion Lifestyle Intervention 1) Raftopoulos Y, et al. Poster at the 37th ASMBS Annual Meeting, 2021. 2) Ienca R, et al. Long-Term Efficacy of the Elipse Gastric Balloon System: An International Multicenter Study, 2020. 3) Ienca R, et al. Sequential Elipse Balloon Treatment 1 Year Weight Loss Results Approximate Bariatric Surgery Results, 2020. © 2024 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION
10 The Allurion Balloon Can Also Impact Co-morbidities, Including Diabetes 1 Positive Early Clinical Results In Diabetic / Pre-diabetic Patients The Allurion Balloon Can Impact Co-morbidities In a study of 518 patients (225 w. diabetes / 293 w. pre-diabetes), majority In 115 patients treated with the Allurion program with of patients entered remission four months after balloon insertion co-morbidities, resolution rates were greater than 50% 2 Percentage of Patients With Resolution of Co-Morbidity HbA1c (%) 23% on average 59% 14% on average 58% 7.1% 5.9% 5.5% 5.1% 56% Diabetes Pre-diabetes Type 2 diabetes Hypertension Obstructive sleep apnea A1c before balloon placement A1c after balloon placement 1) Ienca R, et al. Oral presentation at IFSO; Napoli, Italy, 2023. 2) Mathur W, et al. “Effect of swallow balloon therapy with the combination of semaglutide oral formulation: A randomised double-blind single-centre study.” Obesity Surgery, 2023. 3) Ienca R, Oyola C, Giardiello C, et al. The Swallowable Gastric Balloon: Global Experience in 5003 Consecutive Patients - The Largest Gastric Balloon Study in the World. Oral presentation at IFSO; Napoli, Italy, 2023. © 2024 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION
11 The Allurion Balloon Was Designed To Be Safer Than Alternatives Allurion Results Demonstrate Tolerance Compared to Other Balloons, The Allurion Balloon Thanks To A Unique Design Results In Fewer Serious Adverse Events (SAEs) Device- or procedure-related SAE rates 10.0% Conforms to the shape of the 01 stomach – an oval shape like a 7.5% grapefruit, with two flat surfaces 5.3% N=1,770 0.4% Made from polyurethane – thinner 02 and more flexible than the silicone Spatz ReShape Orbera Allurion (Ienca et al.) in endoscopic balloons SAE rate over 10X lower than other liquid- filled balloons* Designed to be gentle on the 03 stomach lining and reduce GI adverse events and intolerance Intolerance rates for endoscopic balloons are 4, 5 7-8X higher than the Allurion Balloon 1) Spatz SSED (Nov 2021); 2. ReShape SSED (Jul 2015), 3. Orbera SSED (Aug 2015); 4. Jamal MH, et al. Obes Surg. 2021;31(12):5342-5347; 5. Abu Dayyeh et al. Lancet. 2021. *ReShape, Orbera, and Allurion were not compared in head-to-head studies. © 2024 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION
12 2 Billion Adults Globally with BMI 25+: Large Opportunity in Existing and Future Markets UK Canada Italy Currently launched in 50+ countries that represent France USA Spain 40% of BMI 25+ China Population Mexico UAE India U.S. and China represent Brazil 46% Pre-2022 Launches of BMI 25+ Saudi 2022 Launches Population* Arabia Australia Future Launches Source: Allurion market research. Note: *Future launches subject to obtaining regulatory approvals. EU market subject to renewal of approval. Allurion Balloon is currently not approved for sale in the United States. © 2024 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION
13 Commercial Performance Allurion’s innovative technology has enabled deep penetration into international markets At a Glance Historical Financials and Procedural Volume 2024 Outlook Revenue ($ in millions) Gross Margin (%) 2023 YoY revenue impacted by Strong management track record macroeconomic headwinds and Revenue Gross Margin of delivering high procedure $80 100% rising GLP-1 demand volume growth (1) $64 $60-$65 4w4 $60 $53 Revenue decreased despite $38 procedural volume growth, $40 80% reflecting inventory destocking Over 150,000 patients treated $20 beginning in Q4 2023 worldwide, delivered in over 1,500 $20 partner clinics $0 60% Continued growth in procedural 2020A 2021A 2022A 2023A 2024E volumes (12% YoY in 1Q ’24; Guidance targeting 20% YoY 2024) Targeting 80%+ gross margin, with a plan to drive towards profitability Implemented strategic cost reduction effort in order to New App User Volume decrease operating expenses 30,215 31% Growth will be catalyzed by Expected to reduce 2024 cash YoY expansion in existing territories, Growth digital platform expansion, and burn to approximately $30 million 23,096 2 entry into the US market from $64 million in 2023 2022 2023 (1) Represents the midpoint of the range 2024E revenue range of $60-$65M and gross margin range of 77.0 – 79..0% stated by Company in 1Q 2024 earnings release. (2) The Allurion Balloon is an investigational device in the United States and has not been cleared or approved by the U.S. Food and Drug Administration (FDA). In rare cases, endoscopic or surgical intervention may be required for removal. © 2024 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION
14 Macroeconomic And De-stocking Headwinds Are Abating In 2024 Procedure volume reflects health of underlying demand and is Q1 results showed growth in revenue and procedure volumes indicative of higher revenue run-rate Quarterly revenue ($M) New App Users (NAU) Quarterly revenue ($M) $13.9 ~22% ~14% $11.4 $9.4 $9.4 $8.2 $8.2 4Q 2023 1Q 2024 4Q 2023 1Q 2024 4Q 2023 1Q 2024 1 Recognized Revenue Theoretical Procedure Revenue Pro-forma 1Q24 revenue of ~$14M if procedure volume and Procedure volume growth out-pacing revenue growth, leading to reduction in channel inventory revenue aligned Over time, recognized revenue should marginally exceed Anticipating 20% YoY procedure volume growth in 2024 procedure revenue ~12% YoY growth in new app users in 1Q’24 exceeded expectations 1) Procedure Volume estimated as New App Users who log an Allurion Balloon placement over a given period. Theoretical procedure revenue defined as balloon placements * average selling price per balloon after historical experience. © 2024 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION
15 US Opportunity Our market research indicates that the US market is large and attractive US Market Opportunity 100% Total population of the US 342 million Target ages (18-76) and 28.1% target BMI (30-40) $18B 96.2 million US TAM* 21.7% Target household income 74.3 million 17.1% Bothered by their weight 58.5 million 11.2% Ready to act in the next 2 years 38.3 million ~10M Would consider HCP 5.9% US Addressable Market intervention 20.2 million Population 3.0% Would consider Allurion 10.3 million Note: *Assuming price of $1,750 per balloon. © 2024 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION
16 US Opportunity AUDACITY trial enrollment completed in Fall 2023, and data is expected by year-end 2024 W0 W16 W24 W40 W48 Balloon 1 Break Balloon 2 Break Moderate Intensity Lifestyle Therapy Treatment Group (n = 250) Moderate Intensity Lifestyle Therapy Control Group (n = 250) Co-Primary 50% responder rate 3.0% total body weight loss (TBWL) Endpoints: (>5% TBWL) at 48 weeks superiority margin at 48 weeks Open-label, sequential balloon Conservative 48-week endpoint design is expected to boost weight sample size may open door to loss and durability and powering reimbursement © 2024 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION
17 Previous Open-Label Balloon Studies Have Shown Significant Weight Loss In the Treatment Group Open Label Studies Sham Controlled Studies Weight Loss Results from pivotal, open-label (% TBWL) -6.9 -11.6 -3.2 -3.5 balloon studies show higher weight loss in the treatment group and similar weight loss in 14.9 the control group versus sham- controlled studies 10.2 Control group weight loss may attenuate further beyond 8 months due to weight re-gain 6.8 6.6 AUDACITY is an open-label 3.4 3.3 3.3 3.3 design with primary endpoints measured at 12 months Orbera Spatz3 Obalon ReShape Treatment group Control group Treatment group Control group Source: Ienca et al. Sequential Elipse Balloon Treatment: 1-Year Weight Loss Results Approximate Bariatric Surgery Results. Orbera SSED (Aug 2015). © 2024 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION
18 Virtual Care Suite VCS software commercialization is an incremental revenue opportunity Commercialization Opportunity Early Strategic Partnerships Germany's largest weight loss clinic chain with 18 locations worldwide VCS including AI-powered 2,000+ patients on-boarded in coaching 2023 and renewed 2024 Current Commercialization Potential commitment UK’s largest aesthetic and weight loss clinic chain with 17 locations BALLOON BARIATIC GLP-1 Recently signed for 2024 SURGERY DRUGS Allurion’s VCS has already launched in the US France's largest aesthetic and Powered by Coach Iris, the VCS can be deployed across other weight loss weight loss clinic with 160+ solutions locations worldwide Increasing commercialization efforts leveraging existing balloon footprint Recently signed for 2024 Already have a promising pipeline of weight loss chains globally interested in partnering © 2024 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION
19 Impact of GLP-1s and Allurion’s Opportunity ~25% of patients tried prescription weight-loss drugs before starting the Allurion Program GLP-1s have several drawbacks… …that have created new opportunities for Allurion 45% of Allurion providers Poor Experience believed anti-obesity medications boosted awareness / interest in Allurion Weekly injections needed 1 Only 22% of patients remain on therapy after one year The Allurion Balloon observed to impact co-morbidities, either as a standalone treatment or combined with a GLP-1 Potential Risks 2 6 Thyroid cancer associated with LT use Percentage of Patients With Resolution of Co-Morbidity By Treatment Group 3 Gastrointestinal adverse events 72% High Costs 65% 64% Costs ~$1,000 per month in U.S. with 4 limited insurance coverage 59% 58% 56% Poor Quality Weight Loss 3 Significant loss of muscle mass Type 2 diabetes Hypertension Obstructive sleep apnea 5 Weight is re-gained quickly when drugs are stopped Balloon only Balloon + GLP-1 1) LifeSci Capital, “Obesity Deep Dive Vol III: Survey Results Part I, Current Market Dynamics”. 2) Bezin et al. Diabetes Care 2023;46(2):384-91. 3) Wilding et al. N Engl J Med 2021;384:989–1002. 4) GoodRx, https://www.goodrx.com/wegovy. 5) Wilding et al. Diabetes Obes Metab. 2022;24(8): 1553-64. 6) Mathur W, et al. “Effect of swallow balloon therapy with the combination of semaglutide oral formulation: A randomised double-blind single-centre study.” Obesity Surgery, 2023. © 2024 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION
20 The Allurion Program Is Anchored By An Innovative Medical Device And Enhanced By The VCS GLP-1 drugs have risen in popularity, however… Sustainable weight loss often requires Provider economics matter behavioral change Allurion helps providers alleviate both issues The Allurion Program supports sustainable The Allurion Program creates new revenue weight loss opportunities for providers 96% of average weight loss sustained Offers providers a massive revenue 1 after 1 year opportunity VCS now supports other obesity Creates a route-to-market for providers treatments, including GLP-1s, through that have been traditionally locked out personalized behavior change programs of the weight loss market 1) Ienca R, Giardiello C, Schiano Di Cola R, et al. The Evolution of the Allurion Program for Long-Term Weight Loss: From Virtual Monitoring to a Virtual Care Suite. Oral presentation at the European Congress of Obesity; Maastricht, Netherlands, 2022. © 2024 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION
21 Strategic Priorities Looking to 2024 and beyond, Allurion will focus on sustainable growth and profitability Invest strategically across key Broaden global presence and markets to drive procedure 1 2 expand into the US market* growth Scale and monetize VCS in Strengthen gross margin and parallel with new products & 3 4 attain profitability indications Leverage GLP-1 tailwinds to Normalize sell-in and 5 6 accelerate revenue growth inventory levels Note: *The Allurion Balloon is an investigational device in the United States and has not been cleared or approved by the U.S. Food and Drug Administration (FDA). In rare cases, endoscopic or surgical intervention may be required for removal. © 2024 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION
22 Future Catalysts There are several catalysts that could deliver additional upside Reimbursement New Treatment 8-Month Allurion Expansion of Digital Medtronic Strategic Markets Indications Balloon Solutions Partnership Expand reimbursement Recent studies Development of an 8- Supporting further Expands use of the revenues, building on supported the potential month balloon to development of VCS and Allurion Program in initial successes with of the Allurion Balloon in increase weight loss and the app to expand B2C Medtronic’s bariatric the NHS in the UK and treating Type 2 diabetes, serve higher-BMI and B2B penetration surgery channels entering new hypertension, and populations 1 reimbursement markets obstructive sleep apnea in other geographies 1) Mathur W, et al. “Effect of swallow balloon therapy with the combination of semaglutide oral formulation: A randomised double-blind single-centre study.” Obesity Surgery, 2023. © 2024 ALLURION TECHNOLOGIES - PROPRIETARY INFORMATION
